Thursday, 21 August 2003: 07:00-08:30 | |||
S116 Neuroprotection: Basic Science Data and Clinical Implications | |||
| Recent basic science research has demonstrated robust potential for neuroprotective effects of several agents. This is often assessed in bench research via the impact on bcl-2, a potent neuroprotective factor, and GSK-3 beta, a neuronal death enzyme. Intriguing studies by Manji and colleagues at the NIMH have demonstrated neuroprotective and neurotrophic effects of mood stabilizers. Chronic lithium administration has been shown to increase gray matter in human studies. Similarly, divalproex has also been shown to influence neuritic growth and growth cone formation. However, further research is needed to determine the clinical relevance of these data. An overview of the molecular and cellular mechanisms regulating cell atrophy, cell survival and neurogenesis in the CNS, and the regulation of these processes will be reviewed. Data demonstrating the major neurotrophic effects of various pharmaceutical agents will be presented and current studies that exploit specifically the ability of mood stabilizers to reverse disease-associated neuronal atrophy and cell death will be reviewed. This includes an ongoing clinical trial of extended-release divalproex in combination with donepezil for potential cognitive enhancement in Alzheimer’s disease patients. This study is also assessing hippocampal volume and shape, and the impact of these medications on patient behavior. Finally, the clinical implications of these data in the treatment of other neurodegenerative diseases will be discussed. | |||
| Chair: | Peter Aupperle | ||
| S116-001 The Basics of Neuroprotection Steven T. DeKosky | |||
| S116-002 Neuroprotection in Alzheimer’s Disease: A Clinical Trial Peter Aupperle | |||
| S116-003 The Potential Role of Mood Stabilizers in Neurodegenerative Diseases Lesley Blake | |||
Back to Satellite Symposia
Back to The Eleventh International Congress